Abstract
The results of a multicentre, randomised, double-blind, placebo controlled, crossover trial of lamotrigine as add-on therapy in patients with partial seizures poorly controlled by established antiepileptic drugs (AEDs) are presented. The study consisted of two 12 week treatment periods each followed by a four week washout period. During the lamotrigine treatment phase, patients received 150 mg or 300 mg daily dose depending on their concomitant AEDs to achieve concentrations in the range 1-3 mg/L. Forty one patients were entered at four centres and all patients entered completed the study. There was a highly significant (p < 0.001) decrease in total seizure counts on lamotrigine compared with placebo. Overall, 22% of patients experienced at least a 50% reduction in the total numbers of all seizures types on lamotrigine, compared with none on placebo. When the total numbers of partial seizures (simple and complex partial) were analysed there was also a significant (p < 0.05) reduction in seizure counts on lamotrigine compared with placebo. When total numbers of secondarily generalised seizures were compared the trend for a reduction in this seizure type did not achieve significance (0.05 < p < 0.1). Concomitant AED plasma concentrations were virtually unchanged. It is concluded that lamotrigine is an effective AED in the treatment of therapy-resistant partial seizures.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Binnie C. D., Debets R. M., Engelsman M., Meijer J. W., Meinardi H., Overweg J., Peck A. W., Van Wieringen A., Yuen W. C. Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilepsy Res. 1989 Nov-Dec;4(3):222–229. doi: 10.1016/0920-1211(89)90007-7. [DOI] [PubMed] [Google Scholar]
- Cohen A. F., Land G. S., Breimer D. D., Yuen W. C., Winton C., Peck A. W. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther. 1987 Nov;42(5):535–541. doi: 10.1038/clpt.1987.193. [DOI] [PubMed] [Google Scholar]
- Jawad S., Richens A., Goodwin G., Yuen W. C. Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia. 1989 May-Jun;30(3):356–363. doi: 10.1111/j.1528-1157.1989.tb05309.x. [DOI] [PubMed] [Google Scholar]
- Jawad S., Yuen W. C., Peck A. W., Hamilton M. J., Oxley J. R., Richens A. Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. Epilepsy Res. 1987 May;1(3):194–201. doi: 10.1016/0920-1211(87)90041-6. [DOI] [PubMed] [Google Scholar]
- Leach M. J., Marden C. M., Miller A. A. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia. 1986 Sep-Oct;27(5):490–497. doi: 10.1111/j.1528-1157.1986.tb03573.x. [DOI] [PubMed] [Google Scholar]
- Loiseau P., Yuen A. W., Duché B., Ménager T., Arné-Bès M. C. A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Res. 1990 Nov;7(2):136–145. doi: 10.1016/0920-1211(90)90099-h. [DOI] [PubMed] [Google Scholar]
- Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 1989 Jul-Aug;30(4):389–399. doi: 10.1111/j.1528-1157.1989.tb05316.x. [DOI] [PubMed] [Google Scholar]
- Sander J. W., Patsalos P. N., Oxley J. R., Hamilton M. J., Yuen W. C. A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Res. 1990 Aug;6(3):221–226. doi: 10.1016/0920-1211(90)90077-9. [DOI] [PubMed] [Google Scholar]